Skip Navigation

European Heart Journal 2004 25(23):2169-2170; doi:10.1016/j.ehj.2004.08.011
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steinhubl, S. R.
Right arrow Articles by Topol, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinhubl, S. R.
Right arrow Articles by Topol, E. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Risk reduction with long-term clopidogrel following percutaneous coronary intervention

Steven R. Steinhubla,* and Eric J. Topola,b

a Division of Cardiology, University of Kentucky, Lexington KY, USA
b Division of Cardiology Cleveland Clinic Foundation, Cleveland, OH, USA

Received July 30, 2004; revised July 30, 2004; accepted August 6, 2004 * Corresponding author. Present address: Division of Cardiovascular Medicine, University of Kentucky, 900 S. Limestone Strret, 326 Charles T. Weddington Bulding, Lexington, KY 40536-0284, USA. Tel.: +859 323 8040; fax: +859 323 6475 (E-mail: Steinhubl@uky.edu).

The first 10% of the full text of this article appears below.

Only recently have we begun to appreciate that the mechanical treatment of a haemodynamically significant coronary lesion does not represent conclusive therapy for atherosclerotic disease, but rather serves as a warning for a heightened risk of future events and the need for aggressive preventative therapies. A recently published analysis attempted to quantify . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ. Res.Home page
T. A. Meadows and D. L. Bhatt
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Circ. Res., May 11, 2007; 100(9): 1261 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
H. Hamdalla and S. R. Steinhubl
Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G20 - G24.
[Abstract] [Full Text] [PDF]